10-Q: Goldenwell Biotech Q3 2025: Losses Narrow, Cash Dwindles

Goldenwell Biotech reported a reduced net loss in Q3 2025, driven by new service revenue, but faces significant liquidity challenges and ineffective disclosure controls.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $47,581 from $103,962 in the prior year period.
• Service revenue increased to $62,500 for the nine months ended September 30, 2025, compared to $0 in the same period last year, offsetting a decline in sales revenue from $297 to $0.
• Cash balance decreased to $45,622 as of September 30, 2025, from $49,404 at December 31, 2024.
• The company reported a negative working capital balance of $(94,823) as of September 30, 2025.
• Accumulated net loss since inception reached $1,407,226.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.
• The company requires approximately $5,000,000 to construct manufacturing facilities and train its workforce, with no financing currently arranged.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position with a going concern warning, negative working capital, and ineffective disclosure controls. While net loss improved and service revenue emerged, the lack of secured funding for critical future operations and zero product sales indicate severe challenges and high risk.

Positives

• Net loss for the nine months ended September 30, 2025, improved significantly to $47,581, compared to $103,962 for the same period in 2024.
• Operating income improved to a loss of $(41,281) for the nine months ended September 30, 2025, from a loss of $(99,762) in the prior year.
• The company generated $62,500 in service revenue for the nine months ended September 30, 2025, a new revenue stream compared to $0 in 2024.
• Net cash used in operating activities significantly decreased to $(3,781) for the nine months ended September 30, 2025, from $(97,726) in the prior year.
• Cash at the end of the period was $45,622, higher than $4,755 at the end of the prior year period.

Negatives

• The company has sustained an accumulated net loss of $1,407,226 since its inception.
• Cash balance decreased from $49,404 at December 31, 2024, to $45,622 at September 30, 2025.
• Sales revenue for the nine months ended September 30, 2025, was $0, down from $297 in the prior year period.
• Working capital balance is negative at $(94,823) as of September 30, 2025.
• Total liabilities increased to $315,233 as of September 30, 2025, from $271,433 at December 31, 2024.
• Stockholders' equity is negative at $(94,823) as of September 30, 2025, further deteriorating from $(47,241) at December 31, 2024.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025.
• The company has no financing arranged to fund its business plan and expansion.

Risks

• The company's continuation as a going concern is dependent upon its ability to generate revenues and obtain capital from third parties, with no assurance of success.
• Actual results may differ materially from forward-looking statements due to factors such as product demand, market and customer acceptance, competition, pricing, climate change, pandemics, political changes, and development difficulties.
• The company requires approximately $5,000,000 to construct manufacturing facilities and train its workforce, with no guarantee of raising these funds.
• Failure to raise sufficient funding from equity financing or other sources will lead to the business failing.
• Existing shareholders will experience dilution if the company is successful in completing an equity financing.
• Disclosure controls and procedures were not effective, indicating a risk in the accuracy and timeliness of financial reporting.

Future Outlook

The company plans to increase sales of its products and raise additional funds through debt or equity offerings to fund the construction of manufacturing facilities and workforce training, which is estimated to cost approximately $5,000,000 and take about one year to complete. However, no financing is currently arranged, and there is no guarantee of securing sufficient funds.

Management Comments

• The Company is in the development stage whose purpose is R&D, production and sales health cares and supplements products.
• The Companys continuation as a going concern is dependent upon, among other things, its ability to generate revenues and its ability to obtain capital from third parties.
• No assurance can be given that the Company will be successful in these efforts.
• The Company plans to raise additional funds through debt or equity offerings. There is no guarantee that the Company will be able to raise any capital through this or any other offerings.
• We estimate that we need approximately $5,000,000 to complete such activities [constructing manufacturing facilities and training workforce] and that it would take approximately one year to complete such activities.
• If we are unable to achieve the financing necessary to continue our plan of operations, then we will not be able to continue the expansion of our business.
• Based on that evaluation, our Chief Executive Officer and our Secretary concluded that, as of September 30, 2025, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our President and our Secretary, as appropriate, to allow timely decisions regarding required disclosure.

Industry Context

Goldenwell Biotech operates in the health care and supplements industry, a competitive market. As a development-stage company, it is attempting to establish manufacturing capabilities and increase product sales, a common challenge for new entrants. The reliance on external financing for significant capital expenditures is typical for companies at this stage, but the lack of secured funding and ineffective internal controls present substantial hurdles compared to more established industry players.

Comparison to Industry Standards

• Compared to established biotech or nutraceutical companies, Goldenwell Biotech's revenue generation is minimal, with $0 in sales for the nine months ended September 30, 2025, indicating it is far from commercialization or significant market penetration.
• The accumulated net loss of over $1.4 million and negative working capital of $(94,823) are indicative of a pre-revenue or early-stage company, but the going concern warning and lack of secured funding for critical infrastructure (estimated $5 million for manufacturing) place it significantly behind peers that have successfully raised capital for such development.
• The disclosure of 'not effective' disclosure controls and procedures is a serious governance issue that would be unacceptable for a mature public company and raises concerns about financial reporting reliability compared to industry best practices.
• The reliance on related-party loans for a significant portion of its non-current liabilities ($95,588 from the CEO) suggests difficulty in attracting arm's-length financing, a stark contrast to well-capitalized industry participants.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any legal proceedings that are likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• On June 7, 2021, the company purchased inventory of $103,125 from Australian Trefoil Heath Technology, which is owned by Li, Yang, the Treasurer of the company.
• The company borrowed long-term loans totaling $95,588 as of September 30, 2025, from Shuang Liu, the Chief Executive Officer of the company, across multiple dates in 2022 and 2023. This amount is classified as a noncurrent liability on the balance sheet.

Stakeholder Impact

• Shareholders: Face significant risk of dilution from potential equity financing and the possibility of business failure if capital is not raised. Current equity is negative.
• Creditors: The company has substantial liabilities, including related-party loans, and a going concern warning, indicating high risk for repayment.
• Employees: Future employment is uncertain given the company's dependence on securing significant capital for operations and expansion.
• Customers: Potential for disruption in product availability if manufacturing facilities are not established or if the business fails.

Next Steps

• Increase sales of existing products.
• Raise additional funds through debt or equity offerings.
• Construct manufacturing facilities (locate site, install workshop, set up equipment).
• Train workforce.

Key Dates

Recommendation

Goldenwell Biotech presents an extremely high-risk investment profile. The company is a development-stage entity with a 'going concern' warning, negative working capital, and an accumulated deficit exceeding $1.4 million. While the net loss narrowed and service revenue appeared, product sales are zero. Crucially, management explicitly states that disclosure controls are 'not effective,' a severe governance red flag. The company requires $5 million for essential manufacturing infrastructure but has 'no financing arranged' and 'no guarantee' of securing it, explicitly stating the business will fail without it. This combination of severe financial distress, operational uncertainty, and governance issues makes the stock highly speculative with a significant risk of total loss, warranting a strong sell recommendation.

Keywords

Biotech, Health Care, Supplements, Nutraceuticals, SEC Filing, 10-Q, Financial Results, Going Concern, Liquidity, Capital Raise, Net Loss, Service Revenue, Disclosure Controls, Development Stage